A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China

Oxaliplatin plus S-1 (SOX) was a first-line regimen for advanced gastric cancer. The continuous administration of S-1 for 3 weeks can result in unacceptable gastrointestinal and hematological toxicities. Therefore, an alternative regimen (administration of S-1 for 1-week followed by 1-week rest) is...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Cheng, Qian, Jiong, Zheng, Yulong, Song, Fang, Wang, Qiangfeng, Jiang, Haiping, Mao, Chenyu, Xu, Nong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531169/
https://www.ncbi.nlm.nih.gov/pubmed/31096513
http://dx.doi.org/10.1097/MD.0000000000015696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531169/
https://www.ncbi.nlm.nih.gov/pubmed/31096513
http://dx.doi.org/10.1097/MD.0000000000015696

Ejemplares similares